Nucleome Therapeutics appoints Dr Phil Boyd as Chief Financial Officer

Nucleome Therapeutics appoints Dr Phil Boyd as Chief Financial Officer Phil brings more than 20 years of top-flight financial experience in the life sciences industry Oxford, UK

Related Keywords

United Kingdom ,Kostenloser Wertpapierhandel ,Tiziana Lifesciences ,Phil Boyd ,Danuta Jeziorska ,Leeds University ,Oxford Sciences Innovation ,Bioindustry Association ,University Of Oxford ,Audit Committee For United Kingdom Biocentre ,Durham University Business School ,Royal Society Of Biology ,Consilium Strategic Communications ,Nucleome Therapeutics ,Chief Financial Officer ,Chief Executive Officer ,Enterprise Therapeutics ,Non Executive Director ,Audit Committee ,Caldan Therapeutics ,Oxford Biodynamics ,Finance Committee ,Royal Society ,Visiting Fellow ,Durham University Business ,Oxford Sciences ,Nucleome ,Herapeutics ,Ppoints ,Phil ,Boyd ,Chief ,Financial ,Officer ,